Body mass index trajectories in childhood and incidence rates of type 2 diabetes and coronary heart disease in adulthood: A cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 692 KB, PDF-dokument

  • Kim Blond
  • Dorte Vistisen
  • Julie Aarestrup
  • Lise G. Bjerregaard
  • Mohammed T. Hudda
  • Tjønneland, Anne
  • Kristine H. Allin
  • Marit E. Jørgensen
  • Britt W. Jensen
  • Jennifer L. Baker

Aims: We examined associations between five body mass index (BMI) trajectories from ages 6–15 years and register-based adult-onset type 2 diabetes mellitus (T2D) and coronary heart disease (CHD) with and without adjustment for adult BMI. Methods: Child and adult BMI came from two Danish cohorts and 13,205 and 13,438 individuals were included in T2D and CHD analyses, respectively. Trajectories were estimated by latent class modelling. Incidence rate ratios (IRRs) were estimated with Poisson regression. Results: In models without adult BMI, compared to the lowest trajectory, among men the T2D IRRs were 0.92 (95 %CI:0.77–1.09) for the second lowest trajectory and 1.51 (95 %CI:0.71–3.20) for the highest trajectory. The corresponding IRRs in women were 0.92 (95 %CI:0.74–1.16) and 3.58 (95 %CI:2.30–5.57). In models including adult BMI, compared to the lowest trajectory, T2D IRRs in men were 0.57 (95 %CI:0.47–0.68) for the second lowest trajectory and 0.26 (95 %CI:0.12–0.56) for the highest trajectory. The corresponding IRRs in women were 0.60 (95 %CI:0.48–0.75) and 0.59 (95 %CI:0.36–0.96). The associations were similar in direction, but not statistically significant, for CHD. Conclusions: Incidence rates of adult-onset T2D were greater for a high child BMI trajectory than a low child BMI trajectory, but not in models that included adult BMI.

OriginalsprogEngelsk
Artikelnummer110055
TidsskriftDiabetes Research and Clinical Practice
Vol/bind191
ISSN0168-8227
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This project received funding from The Novo Nordisk Foundation NNF17OC0028338. The funders had no role in the study design, data collection, data analyses, interpretation of results, preparation of the manuscript or the publication process.

Funding Information:
The CSHRR was initiated and planned by Dr. Thorkild I.A. Sørensen and built by the Institute of Preventive Medicine, The Capital Region of Denmark. The authors’ responsibilities were as follows – KB, DV, JA, MTH BWJ and JLB designed the research; KB conducted the analyses; KB, DV, MTH and JLB contributed to the specification of the analyses; JLB and AT provided databases; KB wrote the manuscript; all authors contributed to the interpretation of data; KB and JLB are the guarantors and had primary responsibility for the final content; all authors critically read and edited the manuscript; all authors approved the final manuscript. KB, JA, LGB, MTH, JLB, AT, BWJ and KHA report no conflicts of interest. DV reports shares in Novo Nordisk A/S and has received research grants from Bayer A/S, Sanofi Aventis, Novo Nordisk A/S and Boehringer Ingelheim. MEJ has received research grants from Astra Zeneca, AMGEN, Sanofi Aventis, Novo Nordisk A/S and Boehringer Ingelheim. We will make the data (in de-identified form and to the best of our abilities given legal regulations) used in the manuscript available upon request and pending approval from the steering committee that governs the use of these data. The study protocol and analytic code is also available. Requests may be submitted up to 36 months following article publication. This project received funding from The Novo Nordisk Foundation NNF17OC0028338. The funders had no role in the study design, data collection, data analyses, interpretation of results, preparation of the manuscript or the publication process.

Funding Information:
KB, JA, LGB, MTH, JLB, AT, BWJ and KHA report no conflicts of interest. DV reports shares in Novo Nordisk A/S and has received research grants from Bayer A/S, Sanofi Aventis, Novo Nordisk A/S and Boehringer Ingelheim. MEJ has received research grants from Astra Zeneca, AMGEN, Sanofi Aventis, Novo Nordisk A/S and Boehringer Ingelheim.

Publisher Copyright:
© 2022 The Authors

ID: 320654031